Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

The novel, specific small molecule plasma kallikrein inhibitor ASP-440 normalizes retinal vascular permeability in streptozotocin-induced diabetes

The novel, specific small molecule plasma kallikrein inhibitor ASP-440 normalizes retinal vascular permeability in streptozotocin-induced diabetes. ADA. 2010.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.